Anti-obesity and anti-diabetic effects of CL 316, 243, a highly specific β3-adrenoceptor agonist, in yellow KK mice

This publication has 22 references indexed in Scilit:

• Tissue distribution of beta 3-adrenergic receptor mRNA in man.
  Journal of Clinical Investigation, 1993
• Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent .beta.-adrenergic agonist virtually specific for .beta.3 receptors. A promising antidiabetic and antiobesity agent
  Journal of Medicinal Chemistry, 1992
• Discrepancies in Lipolytic Activities Induced by β-Adrenoceptor Agonists in Human and Rat Adipocytes
  Hormone and Metabolic Research, 1990
• Weight loss in obese subjects on a restricted diet given BRL 26830A, a new atypical adrenoceptor agonist
  BMJ, 1988
• Increased insulin binding and glucose transport in white adipocytes isolated from C57B16obob mice treated with the thermogenic β-adrenoceptor agonist BRL 26830
  Biochemical and Biophysical Research Communications, 1985
• Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs
  Nature, 1984
• Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent
  Diabetes, 1983
• Hamster Brown‐Adipose‐Tissue Mitochondria
  European Journal of Biochemistry, 1976
• Binding and degradation of 125I-labelled insulin by isolated rat fat cells
  Biochimica et Biophysica Acta (BBA) - General Subjects, 1973
• General Survey of Diabetic Features of Yellow KK Mice
  Endocrinologia Japonica, 1970